HSPA5 and synucleinopathy: Although further investigation into molecular mechanisms is still necessary, we anticipate that this therapeutic approach, based on intranasal exogenous GRP78, may contribute to the development of effective therapeutic agents for PD and other synucleinopathies in the future.